Year-end Sale % OFF 
Abstract
e15255 Background: The treatment of progressive pancreatic cancer after front-line chemotherapy is under investigation. Pretreated tumors express cancer stem cell markers and P-glycoprotein. Itraconazole, a common antifungal agent, is a potent inhibitor of the Hedgehog pathway, P-glycoprotein, and angiogenesis. We aimed to evaluate the efficacy and feasibility of chemotherapy with itraconazole for treating progressive pancreatic cancer. Methods: We retrospectively reviewed the medical charts of histologically diagnosed pancreatic cancer patients who had received one or more lines of chemotherapy and subsequent chemotherapy with itraconazole. The efficacy of itraconazole was evaluated according to the Response Evaluation Criteria in Solid Tumors, version 1.1 by considering the survival after chemotherapy with itraconazole. Results: Between 2008 and 2013, we enrolled 38 recurrent patients. All the patients were referred to our institution from tertiary care hospitals; they received docetaxel (35 mg/m2), gem...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
